An independent peptide reference
What does this peptide actually do?
For every peptide: how it works, what the research really shows, dosing from the literature, and a reconstitution calculator. No sellers, nothing promoted, every claim sourced.
Popular: GLP-1 & weight loss · Growth hormone · Recovery & healing · Nootropics · Hormonal & sexual · Immune & longevity · Skin & cosmetic
Peptides
5-Amino-1MQ
preclinical5-amino-1-methylquinolinium · 5A1MQ
Not a peptide but a small molecule that blocks the enzyme NNMT; studied in mice only, never in a human trial.
Abaloparatide
clinically provenTymlos · Eladynos
Synthetic PTHrP(1-34) analogue, a daily 80 mcg injection that builds bone in osteoporosis.
ACE-031
early-clinicalramatercept · ActRIIB-Fc
A myostatin-trapping receptor fusion protein whose clinical development was stopped for vascular bleeding events.
Acetyl tetrapeptide-3
preclinicalAc-KGHK-NH2 · Component of Capixyl
Topical tetrapeptide used mainly in hair and scalp products, marketed for follicle anchoring and matrix support.
Acetyl tetrapeptide-5
preclinicalEyeseryl · Ac-Ala-His-Ser-His-NH2
The dominant 'eye bag' cosmetic peptide; its evidence is one manufacturer trial of about twenty people.
Adamax
preclinicalAdamax peptide
A peptide sold to the nootropic market whose identity cannot be established from any non-vendor source.
Adipotide
preclinicalFTPP · prohibitin-targeting peptide
Preclinical peptide that kills fat-tissue blood vessels; caused kidney damage in monkeys.
Afamelanotide
clinically provenMelanotan-1 · Melanotan I
Approved alpha-MSH analogue implant for light-induced pain in erythropoietic protoporphyria.
AICAR
early-clinical5-Aminoimidazole-4-carboxamide ribonucleotide · 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside
Not a peptide but an AMPK-activating nucleoside sold as an 'exercise mimetic'; banned by WADA, unproven in people.
Amycretin
early-clinicalZenagamtide · NNC0487-0111
Investigational single-molecule GLP-1 and amylin receptor agonist, in oral and injectable forms.
Anamorelin
clinically provenONO-7643 · RC-1291
Oral ghrelin receptor agonist for cancer cachexia: approved in Japan, refused by the EMA.
AOD-9604
early-clinicalhGH fragment 176-191 · AOD9604
Growth hormone fragment said to stimulate lipolysis, but human studies showed no weight loss.
AOD-9604 + CJC-1295 + Ipamorelin
preclinicalAOD-9604 / CJC-1295 / Ipamorelin blend · fat-loss GH stack
Fat-loss fragment stacked with a GHRH analogue and a GHRP; the trio has no combination study.
ARA-290
early-clinicalcibinetide · helix B surface peptide
Non-erythropoietic EPO-derived 11-peptide that repairs small nerve fibres; development halted after phase 2.
Argireline
early-clinicalAcetyl hexapeptide-8 · Acetyl hexapeptide-3
Topical hexapeptide that inhibits SNARE complex formation and is said to soften expression lines.
BPC-157
preclinicalBody Protection Compound 157 · PL 14736
Synthetic pentadecapeptide that speeds tissue repair in animal studies; human efficacy is unproven.
BPC-157 + TB-500
preclinicalBPC-157/TB-500 blend · BPC-157 & TB-500 recovery blend
BPC-157 and TB-500 co-packed as the standard recovery blend; the combination itself has never been studied.
Bromantane
early-clinicalLadasten · Bromantan
Not a peptide but a Russian adamantane stimulant, sold beside Semax and Selank on Russian-only trial data.
Bronchogen
preclinicalAEDL peptide · Ala-Glu-Asp-Leu
Tetrapeptide from the Russian bioregulator programme, studied in rat lung models with no human evidence.
Cagrilintide
early-clinicalAM833 · NNC0174-0833
Long-acting amylin analogue that enhances satiety, studied alone and with semaglutide.
CagriSema
clinically provencagrilintide/semaglutide · cagrilintide-semaglutide
Fixed-dose combination of the amylin analogue cagrilintide with semaglutide; filed with the FDA, not approved.
Calcitonin
clinically provensalmon calcitonin · salcatonin
Thyroid C-cell hormone; the salmon version is used short-term for hypercalcaemia and Paget disease.
Carnosine
early-clinicalBeta-alanyl-L-histidine · L-carnosine
Endogenous dipeptide used topically against glycation and taken orally, where serum carnosinase destroys most of it.
Cartalax
preclinicalAED peptide · Ala-Glu-Asp
Tripeptide from the Russian bioregulator programme, marketed for cartilage with no human evidence.
Cerebrolysin
early-clinicalFPF-1070
Peptide preparation from porcine brain, registered in several countries for stroke and dementia.
Cerluten
preclinicalCerluten Cytomax · brain peptide complex capsule
Bovine brain extract capsule from the Khavinson Cytomax line, with no published study under that name.
Cetrorelix
clinically provenCetrotide · cetrorelix acetate
GnRH antagonist used in IVF: blocks the receptor immediately, suppressing LH without the flare seen with agonists.
Chonluten
preclinicalChonluten T-34 · T-34
Khavinson tripeptide marketed as a lung and bronchial bioregulator, with essentially no clinical evidence.
CJC-1295 + GHRP-2
preclinicalCJC-1295 (no-DAC) / GHRP-2 blend · Mod GRF 1-29 + GHRP-2
A GHRH analogue and GHRP-2 in one vial for pulsatile GH release; the pairing itself is unstudied.
CJC-1295 + Ipamorelin
preclinicalCJC/Ipa · CJC-1295 no-DAC + Ipamorelin
GHRH analogue plus ghrelin receptor agonist: the one common blend with a real rationale, still unstudied as a blend.
CJC-1295 with DAC
early-clinicalCJC-1295 DAC · DAC:GRF
Long-acting GHRH analogue that binds albumin and raises GH release for 6 to 8 days per injection.
Collagen peptides
early-clinicalhydrolysed collagen · collagen hydrolysate
Hydrolysed collagen taken orally; real randomised evidence for joint pain, contested evidence for skin.
Cortagen
preclinicalAEDP peptide · Ala-Glu-Asp-Pro
Khavinson tetrapeptide derived from the amino acid profile of Cortexin, with no independent evidence.
Cortexin
early-clinicalKorteksin · bovine cerebral cortex polypeptide complex
Undefined polypeptide extract of bovine brain cortex, registered in Russia and injected for cognitive complaints.
Danuglipron
early-clinicalPF-06882961
Not a peptide: Pfizer's oral small-molecule GLP-1 agonist, discontinued in 2025 after a liver injury case.
Dasiglucagon
clinically provenZegalogue · ZP4207
Ready-to-use glucagon analogue in an autoinjector for severe hypoglycaemia, with no reconstitution step.
Davunetide
early-clinicalNAP · AL-108
Eight-residue ADNP fragment that failed a large phase 2/3 trial in progressive supranuclear palsy.
Decorin
preclinicalDCN · PG-S2
An endogenous proteoglycan, not a peptide, studied as an anti-fibrotic TGF-beta trap - almost entirely in animals.
Degarelix
clinically provenFirmagon · FE200486
GnRH receptor antagonist for prostate cancer: castrate testosterone within days, with no agonist flare.
Desmopressin
clinically provenDDAVP · 1-desamino-8-D-arginine vasopressin
Synthetic vasopressin analogue used for central diabetes insipidus, bedwetting and mild bleeding disorders.
Dihexa
preclinicalPNB-0408 · N-hexanoyl-Tyr-Ile-(6)aminohexanamide
Preclinical angiotensin IV derivative whose core evidence was retracted in 2025 for data falsification.
DSIP
early-clinicalDelta Sleep-Inducing Peptide · delta sleep-inducing peptide
1974 nonapeptide proposed as a sleep factor, but its sleep effects in humans are inconsistent.
Dulaglutide
clinically provenTrulicity · LY2189265
Once-weekly GLP-1 receptor agonist for type 2 diabetes with proven cardiovascular benefit.
Ecnoglutide
clinically provenXW003
Once-weekly cAMP-biased GLP-1 receptor agonist, approved in China for obesity and diabetes.
Eloralintide
early-clinicalLY3841136
Investigational once-weekly selective amylin receptor agonist for obesity, now in phase 3.
Endoluten
preclinicalEndoluten Cytomax · pineal peptide complex capsule
Bovine pineal extract capsule from the Khavinson Cytomax line, with no published study under that name.
Enobosarm
early-clinicalOstarine · MK-2866
Not a peptide but an oral non-steroidal SARM: heavily trialled, never approved, and a leading doping finding.
Epitalon
preclinicalEpithalon · Epithalone
Synthetic tetrapeptide from Russian bioregulator research, with contested claims about telomerase and lifespan.
Epithalamine
preclinicalEpithalamin · Epitalamin
Bovine pineal gland extract from the Khavinson programme and the source material from which Epitalon was derived.
Exenatide
clinically provenByetta · Bydureon
First-generation GLP-1 receptor agonist for type 2 diabetes, largely withdrawn from the market.
FGL Peptide
preclinicalFGL · FGLL
NCAM-derived FGFR1 agonist peptide with substantial rodent data and no demonstrated clinical benefit.
Follistatin-344
early-clinicalFST-344 · FS-344
A 344-residue follistatin precursor protein that binds myostatin and activin; sold as an injectable with no human data.
FOXO4-DRI
preclinicalFOXO4 D-Retro-Inverso peptide · FOXO4-p53 interfering peptide
Experimental senolytic peptide from a 2017 mouse study, sold to consumers despite zero human safety data.
Ganirelix
clinically provenGanirelix acetate · Fyremadel
GnRH antagonist supplied ready-to-use, given daily during IVF stimulation to prevent a premature LH surge.
GDF-11
preclinicalGrowth Differentiation Factor 11 · GDF11
TGF-beta family protein at the centre of an unresolved scientific dispute about whether it rejuvenates or harms tissue.
GHK
preclinicalglycyl-L-histidyl-L-lysine · Gly-His-Lys
The copper-free tripeptide itself; in the body it binds copper and largely becomes GHK-Cu.
GHK-Cu
early-clinicalcopper peptide · Cu-GHK
Endogenous copper tripeptide, established as a cosmetic ingredient and used as a non-approved injection.
GHRP-1
early-clinicalgrowth hormone-releasing peptide-1 · GHRP1
The least-studied member of the GHRP family; a few small human studies, no development beyond them.
GHRP-2
early-clinicalPralmorelin · Pralmoreline hydrochloride
Ghrelin receptor agonist with strong GH release, but also raises cortisol, prolactin and appetite.
GHRP-6
early-clinicalGrowth Hormone Releasing Peptide-6 · SKF-110679
The first GHRP: ghrelin receptor agonist with marked hunger and a rise in cortisol and prolactin.
GLOW
preclinicalGLOW blend · Glow Protocol
Seller-invented mixture of GHK-Cu, BPC-157 and TB-500; no study has ever been published on it as a blend.
Glucagon
clinically provenGlucaGen · GlucaGen HypoKit
Pancreatic alpha-cell hormone used as an emergency treatment for severe hypoglycaemia.
Glutathione
early-clinicalGSH · L-glutathione
Not a peptide drug but an endogenous tripeptide: the principal intracellular antioxidant.
Gonadorelin
clinically provenGonadorelin · GnRH
Synthetic and identical to endogenous GnRH; registered for diagnostics of the pituitary-gonadal axis.
hCG
clinically provenHuman chorionic gonadotropin · Chorionic gonadotrophin
Placental hormone acting on the LH receptor; licensed for fertility, used off-label alongside testosterone.
Hexarelin
early-clinicalExamorelin · EP-23905
Potent ghrelin receptor agonist with cardiac effects via CD36, but rapid desensitisation and raised cortisol.
hGH Fragment 176-191
preclinicalHGH Frag 176-191 · growth hormone fragment 176-191
C-terminal fragment of growth hormone sold for fat loss, with essentially no human evidence.
hMG
clinically provenHuman menopausal gonadotropin · Menotropin
Menotropin: FSH and LH activity purified from postmenopausal urine, an approved IVF drug used off-label in men.
Humanin
preclinicalHumanin · HN
Mitochondrially encoded 24-amino-acid peptide that inhibits cell death; studied as a marker, not a drug.
IGF-1 DES(1-3)
preclinicaldes(1-3)IGF-1 · DES(1-3)IGF-I
A naturally occurring truncated IGF-1 that escapes its binding proteins; no human studies exist.
IGF-1 LR3
preclinicalLong R3 IGF-1 · LR3-IGF-1
Cell culture reagent and IGF-1 analogue with a real hypoglycaemia risk; not studied in humans.
Insulin
clinically provenhuman insulin · insulin lispro (Humalog)
The archetypal therapeutic peptide: the glucose-lowering pancreatic hormone and its engineered analogues.
Ipamorelin
early-clinicalNNC 26-0161 · Ipamorelin acetate
Selective ghrelin receptor agonist (GHRP) that releases growth hormone without raising cortisol or prolactin.
Kisspeptin-10
early-clinicalKisspeptin-10 · KP-10
Decapeptide that drives GnRH release via the KISS1R receptor and can thereby raise LH and testosterone.
Klotho
preclinicalalpha-Klotho · α-Klotho
A large longevity-associated membrane protein with strong biology and no consumer product that plausibly delivers it.
KLOW
preclinicalKLOW blend · GLOW + KPV
GLOW with KPV added: a four-peptide vendor mixture with no published research on it as a mixture.
KPV
preclinicallysine-proline-valine · alpha-MSH (11-13)
Anti-inflammatory tripeptide from alpha-MSH; the evidence is entirely preclinical, with no human studies.
KPV + BPC-157
preclinicalBPC-157/KPV blend · gut blend
Two unapproved gut peptides sold as one product; the mixture is unstudied and the route undercuts it.
L-Carnitine
clinically provenLevocarnitine · Carnitine
Not a peptide but an amino-acid derivative; an approved drug for carnitine deficiency, sold unproven for fat loss.
Lactoferrin
early-clinicalLf · LTF
An iron-binding milk protein sold as an oral supplement, with real randomised trial data and genuinely mixed results.
Lanreotide
clinically provenlanreotide acetate · BIM 23014
Depot somatostatin analogue for acromegaly and neuroendocrine tumours, injected once every four weeks.
Larazotide
early-clinicallarazotide acetate · AT-1001
Oral octapeptide that closes tight junctions in the gut; phase 3 in coeliac disease halted for futility.
Leuphasyl
preclinicalPentapeptide-18 · Tyr-D-Ala-Gly-Phe-Leu
Topical enkephalin-analogue pentapeptide marketed for expression lines; almost no independent research exists.
Leuprolide
clinically provenLeuprorelin · Lupron
The most widely used GnRH agonist: flare then profound suppression, given as depots lasting one to six months.
Liraglutide
clinically provenVictoza · Saxenda
Daily GLP-1 receptor agonist for type 2 diabetes and weight management.
Livagen
preclinicalKEDA peptide · Lys-Glu-Asp-Ala
Khavinson tetrapeptide presented as a liver bioregulator, with chromatin claims from a single group.
LL-37
early-clinicalhuman cathelicidin · hCAP-18/LL-37
Endogenous antimicrobial peptide; the phase 2b trial in leg ulcers missed its primary endpoint.
Lonapegsomatropin
clinically provenSkytrofa · lonapegsomatropin-tcgd
Weekly PEG prodrug of growth hormone: the linker cleaves itself and releases unmodified somatropin.
Macimorelin
clinically provenAEZS-130 · EP-01572
Oral ghrelin receptor agonist approved as a single-dose diagnostic test for adult GH deficiency.
Maridebart cafraglutide
early-clinicalMariTide · AMG 133
Investigational monthly antibody-peptide conjugate: GLP-1 receptor agonist plus GIP receptor antagonist.
Matrixyl
early-clinicalPalmitoyl pentapeptide-4 · Pal-KTTKS
Topical matrikine peptide with a fatty acid tail said to stimulate collagen and extracellular matrix.
Matrixyl 3000
preclinicalPalmitoyl tripeptide-1 + palmitoyl tetrapeptide-7 · Pal-GHK + Pal-GQPR
Trade-name blend of two palmitoylated matrikine peptides used topically for wrinkles and skin firmness.
Mazdutide
clinically provenIBI362 · LY3305677
Dual GLP-1 and glucagon receptor agonist, approved in China for weight management and diabetes.
Melanotan II
early-clinicalMelanotan-2 · MT-II
Unapproved melanocortin agonist that tans the skin; reports of melanoma and systemic toxicity.
Metreleptin
clinically provenMyalept · Myalepta
Recombinant leptin analogue used as hormone replacement in lipodystrophy, not for common obesity.
MGF
preclinicalmechano growth factor · IGF-1Ec
The 24-amino-acid E-domain of a mechanically induced IGF-1 splice variant; its muscle effects failed replication.
MK-677
early-clinicalIbutamoren · Ibutamoren mesylate
Not a peptide but an orally active ghrelin receptor agonist raising GH and IGF-1 around the clock.
Mod GRF 1-29
preclinicalCJC-1295 without DAC · CJC-1295 no-DAC
Short-acting GHRH analogue: modified sermorelin triggering a single GH pulse without albumin binding.
MOTS-c
preclinicalMitochondrial ORF of the 12S rRNA type-c · MOTSc
Mitochondrially encoded peptide that regulates metabolism via AMPK; studied almost entirely preclinically.
N-Acetyl Selank Amidate
preclinicalNA-Selank-Amidate · NASA (Selank)
Doubly modified Selank analogue sold by research-chemical vendors, with no published pharmacology of its own.
N-Acetyl Semax Amidate
preclinicalNA-Semax-Amidate · NASA
Doubly modified Semax analogue sold by research-chemical vendors, with no published pharmacology of its own.
NAD+
early-clinicalNicotinamide adenine dinucleotide · NAD
Not a peptide but a coenzyme: central to energy metabolism, popular as an infusion on strikingly thin evidence.
Nafarelin
clinically provenSynarel · nafarelin acetate
GnRH agonist given as a nasal spray for endometriosis and central precocious puberty; flare first, then suppression.
Neuroxelin
preclinicalNeuroxelin blend · Neuroxelin 48 mg
Vendor-named cognitive injectable sold as a 48 mg vial; its actual peptide composition is not disclosed anywhere.
Nicotinamide riboside
early-clinicalNR · Niagen
Not a peptide but a vitamin B3 form: an oral NAD+ precursor, well studied, with modest clinical results.
NMN
early-clinicalNicotinamide mononucleotide · beta-nicotinamide mononucleotide
Not a peptide but a nucleotide: an oral NAD+ precursor that reliably raises NAD+ and reliably little else.
Noopept
early-clinicalOmberacetam · GVS-111
Not a peptide therapeutic but a small dipeptide-derived synthetic drug, registered in Russia as a nootropic.
Octreotide
clinically provenSMS 201-995 · Sandostatin
Long-acting somatostatin analogue that suppresses growth hormone; standard medical therapy for acromegaly.
Orforglipron
clinically provenFoundayo · LY3502970
Not a peptide: an oral small-molecule GLP-1 receptor agonist, approved for weight management.
Ovagen
preclinicalEDL peptide (supplier-stated) · Glu-Asp-Leu (supplier-stated)
Khavinson bioregulator sold for liver support; the marketed product is a synthetic peptide, not a liver extract.
Oxyntomodulin
early-clinicalOXM · glucagon-37
Gut hormone acting on both GLP-1 and glucagon receptors, the model for today's dual agonists.
Oxytocin
clinically provenSyntocinon · Pitocin
Registered obstetric hormone; the popular intranasal use for social behaviour is largely experimental.
P21
preclinicalP021 · Ac-DGGL(adamantyl-Gly)-NH2
Preclinical CNTF-derived peptide, studied in mouse models of Alzheimer's disease.
Palmitoyl tetrapeptide-7
preclinicalPal-GQPR · Rigin
Anti-inflammatory cosmetic peptide; the second half of Matrixyl 3000, with no evidence of its own.
Palmitoyl tripeptide-1
preclinicalPal-GHK · Palmitoyl oligopeptide (older INCI name)
Topical fatty-acid-tailed version of the matrikine GHK, used to signal collagen synthesis in the dermis.
Palmitoyl tripeptide-5
preclinicalSYN-COLL · Syn-Coll
Cosmetic peptide claimed to activate TGF-beta and build collagen; no published clinical trial exists.
Pasireotide
clinically provenSignifor · Signifor LAR
Second-generation somatostatin analogue for Cushing's disease and acromegaly, with a strong hyperglycaemia signal.
PDRN
early-clinicalPolydeoxyribonucleotide · Polynucleotides
Fish-derived DNA fragment mixture injected into skin for rejuvenation — a nucleotide product, not a peptide.
PE 22-28
preclinicalPE22-28 · mini-spadin
Spadin-derived heptapeptide, a TREK-1 potassium-channel blocker with antidepressant effects in rodents only.
PEG-MGF
preclinicalpegylated mechano growth factor · PEGylated IGF-1Ec E-peptide
MGF with a polyethylene glycol chain attached; the long half-life it is sold on has never been measured.
Pegvisomant
clinically provenB2036-PEG · Somavert
Growth hormone receptor antagonist for acromegaly: it blocks GH action rather than GH secretion.
Pemvidutide
early-clinicalALT-801
Investigational balanced GLP-1/glucagon dual agonist studied in MASH and obesity.
Pentadeca Arginate
preclinicalPDA · pentadecapeptide arginate
BPC-157 supplied as an arginine salt; the peptide is identical and no study has ever tested the salt.
Pentapeptide-3
preclinicalVialox · Pentapeptide-3V
Topical peptide modelled on temple viper venom, claimed to block the muscle acetylcholine receptor.
Petrelintide
early-clinicalZP8396
Investigational once-weekly amylin analogue for weight management, without a GLP-1 component.
Phenylpiracetam
early-clinicalPhenotropil · Carphedon
Not a peptide but a piracetam derivative; banned in competition, with clinical data almost only from Russia.
Pinealon
preclinicalEDR peptide · glutamyl-aspartyl-arginine
Tripeptide from the Russian bioregulator programme, neuroprotective claims without independent evidence.
PNC-27
preclinicalp53-derived anticancer peptide PNC-27 · PNC27
Synthetic p53-HDM-2 fusion peptide that lyses cancer-cell membranes in the lab; no human trials, sold to patients.
Pramlintide
clinically provenSymlin · SymlinPen
Synthetic amylin analogue injected with meals as an add-on to insulin in diabetes.
Prostamax
preclinicalKEDP peptide · Lys-Glu-Asp-Pro
Khavinson synthetic tetrapeptide marketed for the prostate; chromatin claims from a single research group.
PT-141
clinically provenBremelanotide · Vyleesi
Melanocortin receptor agonist, approved in the US for low sexual desire in premenopausal women.
PTD-DBM
preclinicalProtein Transduction Domain-Dishevelled Binding Motif · CXXC5-Dvl inhibitor peptide
Cell-penetrating peptide for hair regrowth via CXXC5-Dishevelled disruption; one mouse study, no human data.
PYY(3-36)
early-clinicalPeptide YY 3-36 · PYY3-36
Gut satiety hormone whose anti-obesity development has been repeatedly defeated by nausea.
Retatrutide
early-clinicalReta · LY3437943
Experimental triple agonist of the GIP, GLP-1 and glucagon receptors for obesity.
Selank
early-clinicalTP-7 · Selanc
Tuftsin analogue registered in Russia, used for generalised anxiety disorder and neurasthenia.
Semaglutide
clinically provenOzempic · Wegovy
Long-acting GLP-1 receptor agonist, registered for type 2 diabetes and weight management.
Semax
early-clinicalACTH(4-7)-PGP · (Pro8,Gly9,Pro10)ACTH-(4-10)
Russian-registered heptapeptide derived from ACTH, studied in stroke and cognitive complaints.
Sermorelin
clinically provenGHRH (1-29) · GRF 1-29
The active 1-29 fragment of GHRH; once FDA-approved, withdrawn in 2008 for commercial reasons.
Sermorelin + GHRP-2
preclinicalSermorelin/GHRP-2 blend · Serm/GHRP-2
A withdrawn GHRH medicine pre-mixed with a Japanese diagnostic peptide; sound class rationale, no study of the mixture.
Setmelanotide
clinically provenImcivree · RM-493
MC4 receptor agonist approved for rare genetic obesity caused by defects upstream of MC4R.
sh-Oligopeptide-1
early-clinicalOligopeptide-1 · rhEGF
Recombinant human EGF sold in topical skincare; the evidence and the criticism of it are both substantial.
SLU-PP-332
preclinicalSR9861 · ERR pan-agonist 332
Not a peptide but a small-molecule ERR agonist marketed as an 'exercise mimetic'; rodent data only.
SNAP-8
preclinicalAcetyl octapeptide-3 · Acetyl glutamyl heptapeptide-1
Topical octapeptide, an extended argireline variant aimed at inhibiting SNARE complex formation.
Somapacitan
clinically provenSogroya · somapacitan-beco
Albumin-binding growth hormone analogue injected once weekly instead of daily somatropin.
Somatostatin
clinically provensomatotropin release-inhibiting factor · SRIF
The body's own inhibitory brake on growth hormone release, and the template for octreotide and lanreotide.
Somatrogon
clinically provenNgenla · somatrogon-ghla
Weekly growth hormone fused to three hCG C-terminal peptides, for growth hormone deficiency in children.
Somatropin
clinically provenrecombinant human growth hormone · rhGH
Recombinant human growth hormone itself: a prescription medicine for growth hormone deficiency.
SS-31 (elamipretide)
early-clinicalElamipretide · MTP-131
Mitochondria-targeted tetrapeptide binding cardiolipin; US-approved for Barth syndrome since 2025.
Survodutide
early-clinicalBI 456906
Experimental dual glucagon and GLP-1 receptor agonist for obesity and MASH.
SYN-AKE
preclinicalDipeptide diaminobutyroyl benzylamide diacetate · Syn-Ake
Topical synthetic mimic of a snake venom peptide, intended to block muscle nicotinic acetylcholine receptors.
TB-500
preclinicalAc-LKKTETQ · thymosin beta-4 fragment 17-23
Seven-amino-acid fragment of thymosin beta-4; the clinical evidence concerns the full protein, not this.
Teduglutide
clinically provenGattex · Revestive
DPP-4-resistant GLP-2 analogue that grows intestinal mucosa in short bowel syndrome.
Teriparatide
clinically provenForteo · Forsteo
Recombinant parathyroid hormone fragment (1-34), a daily injection that builds new bone in osteoporosis.
Tesamorelin
clinically provenTH9507 · Egrifta
FDA-approved GHRH analogue that reduces visceral abdominal fat in HIV-associated lipodystrophy.
Tesamorelin + Ipamorelin
preclinicalTesa/Ipa · 2X blend
An approved HIV lipodystrophy drug pre-mixed with an unapproved secretagogue; the mixture has never been studied.
Tesofensine
early-clinicalNS-2330 · NS 2330
Not a peptide: an oral triple monoamine reuptake inhibitor studied for obesity, approved by no regulator.
Testagen
preclinicalKEDG peptide · Lys-Glu-Asp-Gly
Khavinson synthetic tetrapeptide (KEDG) marketed as a male-reproductive bioregulator; essentially unstudied.
Thymalin
early-clinicalTimalin · thymus polypeptide extract
Bovine thymus extract from the Russian bioregulator programme, with mortality claims the evidence cannot carry.
Thymogen
early-clinicalTimogen · Glu-Trp
Synthetic thymic dipeptide registered in Russia; the same molecule failed Western cancer trials as oglufanide.
Thymopentin
early-clinicalTP-5 · TP5
Synthetic pentapeptide fragment of thymopoietin, marketed as a prescription immunomodulator in several countries.
Thymosin alpha-1
clinically provenThymalfasin · Tα1
Synthetic 28-amino-acid thymus peptide, registered in dozens of countries for chronic hepatitis B and C.
Thymosin beta-4
early-clinicalTB4 · Tbeta-4
Endogenous 43-amino-acid actin-sequestering protein; the compound behind almost all TB-500 marketing claims.
Thymulin
preclinicalFacteur Thymique Sérique · FTS
Zinc-dependent nine-amino-acid thymic hormone; well-described physiology, almost no modern clinical research.
Tirzepatide
clinically provenMounjaro · Zepbound
Dual GIP and GLP-1 receptor agonist, registered for type 2 diabetes and weight management.
Tri-Heal
preclinicalTri-Heal blend · Tri-Heal Max
TB-500, BPC-157 and KPV co-packed as a healing blend; the three-way combination has never been studied.
Triptorelin
clinically provenTrelstar · Decapeptyl
Long-acting GnRH agonist: an initial hormone flare followed by sustained suppression of testosterone or oestradiol.
Vasopressin
clinically provenArginine vasopressin · AVP
The body's own antidiuretic hormone, used in intensive care as an intravenous vasopressor in shock.
Ventfort
preclinicalVentfort Cytomax · vessel peptide complex capsule
Calf blood-vessel extract capsule from the Khavinson Cytomax line, with no published study by that name.
Vesugen
preclinicalKED peptide · Lys-Glu-Asp
Khavinson tripeptide presented as a vascular bioregulator, studied almost entirely by its originators.
Vilon
preclinicalKE peptide · Lys-Glu
Dipeptide from the Russian bioregulator programme, presented as a thymus and immune agent without independent evidence.
VIP (vasoactive intestinal peptide)
early-clinicalVasoactive intestinal polypeptide · Aviptadil
Endogenous 28-amino-acid neuropeptide; intranasally known mainly from Shoemaker's CIRS protocol.
VK2735
early-clinicalVK-2735
Investigational dual GLP-1 and GIP receptor agonist in phase 3, in weekly injectable and daily oral forms.
Vladonix
preclinicalVladonix Cytomax · thymus peptide complex capsule
Calf thymus extract capsule from the Khavinson Cytomax line; not the injectable Thymalin, and unstudied.
Zinc-thymulin
early-clinicalZn-thymulin · ZT
Zinc-complexed thymic nonapeptide sprayed on the scalp for hair loss; one small open-label pilot.
Nothing found.
Try another term, or .